Uncommon Bio is a biotechnology company focused on the development of advanced computational methods and technologies to understand and engineer complex biological systems. Their work aims to revolutionize drug discovery and development by leveraging machine learning and other cutting-edge computational techniques.

Uncommon Bio

GFI Europe is dedicated to promoting alternative proteins such as plant-based and cultivated meat. It engages in advocacy for policies and investment to make these options more accessible.

GFI Europe

Powered by breakthrough technology, our vision of a mouth-watering, affordable and healthy protein is fast approaching - we’ve pioneered a strategy to scale cultivated meat that eliminates the industry’s largest cost driver with zero genetic engineering.

Previously known as Higher Steaks Ltd, we’ve successfully scaled from a compact start-up to a dynamic company of 50+ creative scientists, engineers and operators, committed to a massive takeover of the food industry. We’ve developed a scalable production process that can cut costs, drastically reduce waste materials and improve the health of consumers.

We’ve raised capital totalling $37M from Balderton, Lowercarbon Capital, RedAlpine, Sam Altman (Open AI founder) and Max Altman as well as the UK government through a $1.2M Innovate UK grant. 

From the cell to the sizzle, our Uncommon Bacon and Uncommon Belly are packed full of nutritious goodness and fantastic flavour; paving the way for an Uncommonly good future of delicious, healthy and sustainable meat.

Unleash your creativity and join us!


Metric
Company Name	Uncommon Bio	GFI Europe
Symbol
MSH ID	CO:UNCOMMONBIO	ORG:GFIEUROPE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Consumer Services
Industry	Biotechnology	Food and Agriculture
Country	GB	BE
Stage
Employee Count	70
Website	uncommonbio.co	gfieurope.org
LinkedIn	uncommonbio	gfi-europe
Founders

Metric
Market Cap	180M
Enterprise Value
Monthly Web Traffic		18
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CO:UNCOMMONBIO

Uncommon Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue